Unknown

Dataset Information

0

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.


ABSTRACT: The SARS-CoV-2 infection is spreading rapidly worldwide. Efficacious antiviral therapeutics against SARS-CoV-2 is urgently needed. Here, we discovered that protoporphyrin IX (PpIX) and verteporfin, two Food and Drug Administration (FDA)-approved drugs, completely inhibited the cytopathic effect produced by SARS-CoV-2 infection at 1.25 μmol/L and 0.31 μmol/L, respectively, and their EC50 values of reduction of viral RNA were at nanomolar concentrations. The selectivity indices of PpIX and verteporfin were 952.74 and 368.93, respectively, suggesting a broad margin of safety. Importantly, PpIX and verteporfin prevented SARS-CoV-2 infection in mice adenovirally transduced with human angiotensin-converting enzyme 2 (ACE2). The compounds, sharing a porphyrin ring structure, were shown to bind viral receptor ACE2 and interfere with the interaction between ACE2 and the receptor-binding domain of viral S protein. Our study suggests that PpIX and verteporfin are potent antiviral agents against SARS-CoV-2 infection and sheds new light on developing novel chemoprophylaxis and chemotherapy against SARS-CoV-2.

SUBMITTER: Gu C 

PROVIDER: S-EPMC7724564 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection <i>in vitro</i> and in a mouse model expressing human ACE2.

Gu Chenjian C   Wu Yang Y   Guo Huimin H   Zhu Yuanfei Y   Xu Wei W   Wang Yuyan Y   Zhou Yu Y   Sun Zhiping Z   Cai Xia X   Li Yutang Y   Liu Jing J   Huang Zhong Z   Yuan Zhenghong Z   Zhang Rong R   Deng Qiang Q   Qu Di D   Xie Youhua Y  

Science bulletin 20201209 9


The SARS-CoV-2 infection is spreading rapidly worldwide. Efficacious antiviral therapeutics against SARS-CoV-2 is urgently needed. Here, we discovered that protoporphyrin IX (PpIX) and verteporfin, two Food and Drug Administration (FDA)-approved drugs, completely inhibited the cytopathic effect produced by SARS-CoV-2 infection at 1.25 μmol/L and 0.31 μmol/L, respectively, and their EC50 values of reduction of viral RNA were at nanomolar concentrations. The selectivity indices of PpIX and vertepo  ...[more]

Similar Datasets

| S-EPMC8118678 | biostudies-literature
| S-EPMC7668070 | biostudies-literature
| S-EPMC7402043 | biostudies-literature
| S-EPMC7834886 | biostudies-literature
| S-EPMC8620242 | biostudies-literature
| S-EPMC7784661 | biostudies-literature
| S-EPMC8589851 | biostudies-literature
| S-EPMC9653429 | biostudies-literature
| S-EPMC7592233 | biostudies-literature